Showing 3011-3020 of 4166 results for "".
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- Allegro Ophthalmics Receives Approval from FDA for Design of Phase 2b/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd/2481527/Allegro Ophthalmics announced that the company has received agreement from the FDA under a Special Protocol Assessment (SPA) for the design of its phase 2b/3 clinical trial of risuteganib (Luminate) for the treatment of intermediate, dry age-related macular degeneration (AMD).
- Staar Surgical Names Warren Foust Chief Operating Officer; Magda Michna, PhD, Chief Clinical, Regulatory and Medical Affairs Officerhttps://modernod.com/news/staar-surgical-names-warren-foust-chief-operating-officer-magda-michna-phd-chief-clinical-regulatory-and-medical-affairs-officer/2481498/Staar Surgical announced that Warren Foust has been named Chief Operating Officer, and Magda Michna, PhD, has been named Chief Clinical, Regulatory and Medical Affairs Officer. Both positions will report to Staar Surgical’s President and CEO, Tom Frinzi. “The addition of two
- Aldeyra Therapeutics Announces Positive Topline Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease/2481437/Aldeyra Therapeutics announced topline results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug in dry eye disease patients. The primary endpoints of treatment-related serious adverse events in ocular safet
- Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2https://modernod.com/news/frontera-therapeutics-doses-first-patient-in-phase-1-clinical-trial-for-gene-therapy-ft-001-for-the-treatment-of-leber-congenital-amaurosis-2/2481327/Frontera Therapeutics announced that it has dosed the first patient in a phase 1 clinical trial of its lead gene therapy program, FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to a mutation in the RPE65 gene. FT-001 is administered by a
- Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patientshttps://modernod.com/news/viridian-presents-positive-clinical-data-from-ongoing-vrdn-001-phase-12-trial-in-active-thyroid-eye-disease-ted-patients/2481188/Viridian Therapeutics presented positive proof-of-concept data from the 10 mg/kg cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). These data, as well as new in vitro data further characterizing and differentiat
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- Ocular Therapeutix Announces Interim 7-month Data from US Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-7-month-data-from-us-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2481120/Ocular Therapeutix announced interim 7-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The data will b
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi